1-11 of 11
Daniel Ermann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma

Free
Paolo Lopedote, Adrienne Nedved, Lu Chen, Marcus Watkins, Arian Roua, Muhamad Alhaj Moustafa, Seyi Abidoye, Yun Choi, Georgios Pongas, Tony Zhuang, Jean Clement, Megan Searssmith, Laura Sun, Hannah Willis, Brad Kahl, David Bond, Javier Munoz, Izidore S. Lossos, Craig Portell, Michael Wang, Nilanjan Ghosh, Jonathon Cohen, Peter Martin, Jeremy Abramson, Anne Beaven, Patrick Reagan, Daniel Ermann, Taylor Brooks, Ashlee Joseph, Nazila Shafagati, Daniel McLoughlin, Kira Rosenlind, Brian Hill, Nina Wagner-Johnston, Anita Kumar, Umar Farooq, Reem Karmali, Tanaya Shree, Matthew Lunning, Stacy Pak, Alexey Danilov, Yucai Wang, Tycel Phillips
Journal: Blood
Blood (2025) 146 (Supplement 1): 5351.
https://doi.org/10.1182/blood-2025-5351
Published: 2025
Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Free
Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov
Journal: Blood
Blood (2025) 146 (Supplement 1): 883.
https://doi.org/10.1182/blood-2025-883
Published: 2025
Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Free
Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann
Journal: Blood
Blood (2025) 146 (Supplement 1): 6317.
https://doi.org/10.1182/blood-2025-6317
Published: 2025
Journal Articles

Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy

Free
Hannah Willis, Joshua Horns, Kelsey Baron, Allison Bock, Lindsey Fitzgerald, Narendranath Epperla, Harsh Shah, Boyu Hu, Deborah Stephens, Adam Kittai, Daniel Ermann
Journal: Blood
Blood (2025) 146 (Supplement 1): 6316.
https://doi.org/10.1182/blood-2025-6316
Published: 2025
Journal Articles

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Free
Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Rhys Williams, Daniel Ermann
Journal: Blood
Blood (2025) 146 (Supplement 1): 8041.
https://doi.org/10.1182/blood-2025-8041
Published: 2025
Journal Articles

Trials in progress - a Phase II study of pirtobrutinib in combination with rituximab in untreated marginal zone lymphoma (PIONEER-MZL)

Free
Narendranath Epperla, Allison Bock, Boyu Hu, Yizhe Xu, Lindsey Fitzgerald, Daniel Ermann, Harsh Shah, Kelsey Baron, Nancy Bartlett
Journal: Blood
Blood (2025) 146 (Supplement 1): 3616.
https://doi.org/10.1182/blood-2025-3616
Published: 2025
Journal Articles

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies

Free
Kelsey Baron, Charlotte Wagner, Lindsey Fitzgerald, Amber Jacoway, Ausha Marden, Daniel Ermann, Boyu Hu, Harsh Shah, Narendranath Epperla, Allison Bock
Journal: Blood
Blood (2025) 146 (Supplement 1): 4485.
https://doi.org/10.1182/blood-2025-4485
Published: 2025
Journal Articles

Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024

Free
Paul Hampel, Daniel Ermann, Xiaoliang Wang, Peter Kardel, Caitlin Sheetz, Ashis Das, Qianhong Fu, Lee Ding, Gregory Maglinte, Erlene Seymour, Ryan Jacobs
Journal: Blood
Blood (2025) 146 (Supplement 1): 2723.
https://doi.org/10.1182/blood-2025-2723
Published: 2025
Journal Articles

Trials in progress - A phase I study of loncastuximab tesirine and rituximab following stereotactic radiosurgery in patients with primary and secondary central nervous system lymphomas (SOLAR)

Free
Narendranath Epperla, Allison Bock, Yizhe Xu, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Kelsey Baron, Daniel Ermann, Joe Mendez, Lindsay Burt, Donald Cannon, Amit Maity, Joshua Palmer, Iyad Alnahhas, Thomas Ollila
Journal: Blood
Blood (2025) 146 (Supplement 1): 8241.
https://doi.org/10.1182/blood-2025-8241
Published: 2025
Journal Articles

Trials in progress - A phase II study of pemigatinib in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (PERFORM)

Free
Narendranath Epperla, Yizhe Xu, Allison Bock, Kelsey Baron, Lindsey Fitzgerald, Harsh Shah, Daniel Ermann, Lalit Sehgal, Lapo Alinari, Boyu Hu
Journal: Blood
Blood (2025) 146 (Supplement 1): 8235.
https://doi.org/10.1182/blood-2025-8235
Published: 2025
Journal Articles

Racial and Socioeconomic Disparities in the Utilization of Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in the Era of Novel Agents

Free
Victoria A. Vardell, MD, Daniel Ermann, MD, Maryam Gbadamosi-Akindele, MD, Funmi Badejo, Peter T. Silberstein, MD, Srinivas K. Tantravahi, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 423.
https://doi.org/10.1182/blood-2019-130859
Published: 2019